Logo image of OSMT

OSMOTICA PHARMACEUTICALS PLC (OSMT) Stock Fundamental Analysis

NASDAQ:OSMT - Nasdaq - Common Stock

1.11  -0.02 (-1.77%)

After market: 1.08 -0.03 (-2.7%)

Fundamental Rating

2

Taking everything into account, OSMT scores 2 out of 10 in our fundamental rating. OSMT was compared to 198 industry peers in the Pharmaceuticals industry. OSMT has a bad profitability rating. Also its financial health evaluation is rather negative. OSMT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OSMT had negative earnings in the past year.
OSMT Yearly Net Income VS EBIT VS OCF VS FCFOSMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 -100M -200M

1.2 Ratios

Industry RankSector Rank
ROA -100.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSMT Yearly ROA, ROE, ROICOSMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 -50 -100 -150 -200

1.3 Margins

Industry RankSector Rank
OM -105.6%
PM (TTM) -150.14%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSMT Yearly Profit, Operating, Gross MarginsOSMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, OSMT has more shares outstanding
Compared to 1 year ago, OSMT has a worse debt to assets ratio.
OSMT Yearly Shares OutstandingOSMT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M
OSMT Yearly Total Debt VS Total AssetsOSMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 200M 400M 600M 800M

2.2 Solvency

OSMT has an Altman-Z score of -8.99. This is a bad value and indicates that OSMT is not financially healthy and even has some risk of bankruptcy.
OSMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.99
ROIC/WACCN/A
WACCN/A
OSMT Yearly LT Debt VS Equity VS FCFOSMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 0.43 indicates that OSMT may have some problems paying its short term obligations.
A Quick Ratio of 0.42 indicates that OSMT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.42
OSMT Yearly Current Assets VS Current LiabilitesOSMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

OSMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.83%.
The Revenue for OSMT has decreased by -64.06% in the past year. This is quite bad
The Revenue has been decreasing by -5.01% on average over the past years.
EPS 1Y (TTM)-72.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-10.2%
Revenue growth 5Y-5.01%
Sales Q2Q%-96.16%

3.2 Future

Based on estimates for the next years, OSMT will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.87% on average per year.
The Revenue is expected to grow by 35.55% on average over the next years. This is a very strong growth
EPS Next Y18.29%
EPS Next 2Y20.16%
EPS Next 3Y22.05%
EPS Next 5Y9.87%
Revenue Next Year-89.33%
Revenue Next 2Y-43.56%
Revenue Next 3Y-9.27%
Revenue Next 5Y35.55%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OSMT Yearly Revenue VS EstimatesOSMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
OSMT Yearly EPS VS EstimatesOSMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OSMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OSMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSMT Price Earnings VS Forward Price EarningsOSMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.42
OSMT Per share dataOSMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as OSMT's earnings are expected to grow with 22.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.16%
EPS Next 3Y22.05%

More info and screens

0

5. Dividend

5.1 Amount

OSMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OSMOTICA PHARMACEUTICALS PLC

NASDAQ:OSMT (1/18/2022, 8:41:22 PM)

After market: 1.08 -0.03 (-2.7%)

1.11

-0.02 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners3.56%
Ins Owner Change0%
Market Cap70.07M
Analysts84
Price Target5.87 (428.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.96
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB N/A
EV/EBITDA -1.42
EPS(TTM)-1.59
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.16
BVpS0.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -105.6%
PM (TTM) -150.14%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.42
Altman-Z -8.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y18.29%
EPS Next 2Y20.16%
EPS Next 3Y22.05%
EPS Next 5Y9.87%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-10.2%
Revenue growth 5Y-5.01%
Sales Q2Q%-96.16%
Revenue Next Year-89.33%
Revenue Next 2Y-43.56%
Revenue Next 3Y-9.27%
Revenue Next 5Y35.55%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A